TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines …
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
TOKYO, Jan 19, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai …
Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
TOKYO, Nov 7, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its …
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
TOKYO, Oct 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of …
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care
TOKYO, Aug 9, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a …
Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022
TOKYO, Jul 26, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co. Ltd announced today that the company will present research from its Alzheimer’s disease …